Synonyms: 2-(6-Methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; LY 2157299; LY-2157299; LY2157299
Molecular Formula: C22H19N5O
Molecular Weight: 369.42
Linear Structural Formula: C22H19N5O
MDL Number: MFCD12923319
Purity: >=98% (HPLC)
Storage: 2-8C
Biochem Physiol Actions: Galunisertib (LY2157299) is an orally active multikinase inhibitor (IC50 in nM = 80/ALK4, 170/TGFbetaR1, 210/TGbeta?R2, 190/MINK (MAP4K6), 220/RIP2 (RIPK2), 260/CK1alpha, 280/MEKKK4, 310/GAK, 400/CK1epsilon, 470/ALK6 (BMPR1B), 500/B-raf, 510/TNIK) mostly cited for its ALK4 & TGFbeta (TGFbeta) receptors (TGFbeta-RI (ALK5) & TGFbeta-RII) inhibitory activity and anticancer efficacy in vitro (0.1-10 muM) and in vivo (20-100 mg/kg p.o.; mice).